Maria Shirvani, Babak Sayad, Lida Shojaei, Azadeh Amini, Foroud Shahbazi
{"title":"瑞德西韦相关性显著性心动过缓3例报告","authors":"Maria Shirvani, Babak Sayad, Lida Shojaei, Azadeh Amini, Foroud Shahbazi","doi":"10.18502/jthc.v16i2.7390","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.</p>","PeriodicalId":39149,"journal":{"name":"Journal of Tehran University Heart Center","volume":"16 2","pages":"79-83"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/3c/JTHC-16-79.PMC8742862.pdf","citationCount":"6","resultStr":"{\"title\":\"Remdesivir-Associated Significant Bradycardia: A Report of Three Cases.\",\"authors\":\"Maria Shirvani, Babak Sayad, Lida Shojaei, Azadeh Amini, Foroud Shahbazi\",\"doi\":\"10.18502/jthc.v16i2.7390\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.</p>\",\"PeriodicalId\":39149,\"journal\":{\"name\":\"Journal of Tehran University Heart Center\",\"volume\":\"16 2\",\"pages\":\"79-83\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/3c/JTHC-16-79.PMC8742862.pdf\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Tehran University Heart Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/jthc.v16i2.7390\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tehran University Heart Center","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jthc.v16i2.7390","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Remdesivir-Associated Significant Bradycardia: A Report of Three Cases.
Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
